Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY; QDMRK Investigators. Eron JJ Jr, et al. Among authors: nelson m. Lancet Infect Dis. 2011 Dec;11(12):907-15. doi: 10.1016/S1473-3099(11)70196-7. Epub 2011 Sep 18. Lancet Infect Dis. 2011. PMID: 21933752 Clinical Trial.
Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams. Gulick RM, et al. N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152. N Engl J Med. 2008. PMID: 18832244 Free PMC article. Clinical Trial.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y; SENSE Study Group. Geretti AM, et al. J Antimicrob Chemother. 2014 Apr;69(4):1090-7. doi: 10.1093/jac/dkt474. Epub 2013 Nov 27. J Antimicrob Chemother. 2014. PMID: 24284781 Clinical Trial.
The crucial role of bioimage analysts in scientific research and publication.
Cimini BA, Bankhead P, D'Antuono R, Fazeli E, Fernandez-Rodriguez J, Fuster-Barceló C, Haase R, Jambor HK, Jones ML, Jug F, Klemm AH, Kreshuk A, Marcotti S, Martins GG, McArdle S, Miura K, Muñoz-Barrutia A, Murphy LC, Nelson MS, Nørrelykke SF, Paul-Gilloteaux P, Pengo T, Pylvänäinen JW, Pytowski L, Ravera A, Reinke A, Rekik Y, Strambio-De-Castillia C, Thédié D, Uhlmann V, Umney O, Wiggins L, Eliceiri KW. Cimini BA, et al. Among authors: nelson ms. J Cell Sci. 2024 Oct 15;137(20):jcs262322. doi: 10.1242/jcs.262322. Epub 2024 Oct 30. J Cell Sci. 2024. PMID: 39475207 Review.
SYNCHRONIZE: Real-World Retrospective Safety Analysis of Patients Treated with OnabotulinumtoxinA for More than One Therapeutic Indication.
Forde G, Brucker BM, Becker Ifantides K, Patel AT, Mayadev A, Brown T, Ayyoub Z, Martinez K, Singh R, Nelson M, Battucci S, Yushmanova I, Ukah A, Rhyne C. Forde G, et al. Among authors: nelson m. Toxins (Basel). 2024 Sep 29;16(10):420. doi: 10.3390/toxins16100420. Toxins (Basel). 2024. PMID: 39453196 Free PMC article.
Building common understanding: seeking consensus and defining social prescribing across contexts - a collective commentary on a Delphi study.
Muhl C, Mulligan K, Giurca BC, Polley MJ, Bloch G, Nowak DA, Osborn-Forde C, Hsiung S, Lee KH, Herrmann WJ, Baker JR, Stokes-Lampard DHJ, Everington SS, Dixon M, Wachsmuth I, Figueiredo C, Skjerning HT, Rojatz D, Chen YD, Heijnders ML, Wallace C, Howarth M, Watanabe D, Bertotti M, Jansson AH, Althini S, Holzinger F, Dooler DG, Brand S, Anfilogoff TJ, Fancourt D, Nelson MLA, Tierney S, Leitch A, Nam HK, Card KG, Hayes D, Slade S, Essam MA, Palmer GA, Welch VA, Robinson D, Hilsgen L, Taylor N, Nielsen RØ, Vidovic D, McDaid EM, Hoffmeister LV, Bonehill J, Siegel A, Bártová A, Acurio-Páez D, Mendive JM, Husk K. Muhl C, et al. Among authors: nelson mla. BMC Health Serv Res. 2024 Oct 24;24(1):1280. doi: 10.1186/s12913-024-11603-x. BMC Health Serv Res. 2024. PMID: 39449029 Free PMC article.
5,486 results